SCHEMBL3019528

SCHEMBL3019528

O=S(=O)(c1ccc(CBr)cc1)N1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 5/20 0.42
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
POLB P06746 2/20 0.40
LMNA P02545 4/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
ALOX12 P18054 1/20 0.39
GBA1 P04062 3/20 0.39
THRB P10828 1/20 0.38
LSS P48449 2/20 0.37
LPAR1 Q92633 1/20 0.37
LPAR2 Q9HBW0 1/20 0.37
PKM P14618 2/20 0.37
HTT P42858 2/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023014 0.93 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3016148 0.93 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3018492 0.93 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3015402 0.92 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3012883 0.92 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3018157 0.92 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3008811 0.91 THRB (0.47) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3022160 0.91 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3006932 0.90 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10
SCHEMBL3008158 0.90 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.